XBiotech Faces Uphill Task With Xilonix
Texas-based biotech XBiotech is going to find it tough to persuade clinicians and regulators about the usefulness of it its human antibody Xilonix after it discontinued the second Phase III study of the human antibody, in US colorectal cancer patients.
You may also be interested in...
Where now for XBiotech? The US firm says that despite a big setback for Xilonix in the EU, it will continue to develop the product in oncology.
The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.